{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T19:52:45Z","timestamp":1786305165239,"version":"build-2736575974"},"reference-count":117,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI132213"],"award-info":[{"award-number":["R01AI132213"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Development of preventive vaccines against hepatitis C virus (HCV) remains one of the main strategies in achieving global elimination of the disease. The effort is focused on the quest for vaccines capable of inducing protective cross-neutralizing humoral and cellular immune responses, which in turn dictate the need for rationally designed cross-genotype vaccine antigens and potent immunoadjuvants systems. This review provides an assessment of the current state of knowledge on immunopotentiating compounds and vaccine delivery systems capable of enhancing HCV antigen-specific immune responses, while focusing on the synergy and interplay of two modalities. Structural, physico-chemical, and biophysical features of these systems are discussed in conjunction with the analysis of their in vivo performance. Extreme genetic diversity of HCV-a well-known hurdle in the development of an HCV vaccine, may also present a challenge in a search for an effective immunoadjuvant, as the effort necessitates systematic and comparative screening of rationally designed antigenic constructs. The progress may be accelerated if the preference is given to well-defined molecular immunoadjuvants with greater formulation flexibility and adaptability, including those capable of spontaneous self-assembly behavior, while maintaining their robust immunopotentiating and delivery capabilities.<\/jats:p>","DOI":"10.3390\/v13060981","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T22:02:23Z","timestamp":1621980143000},"page":"981","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunopotentiating and Delivery Systems for HCV Vaccines"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-6156","authenticated-orcid":false,"given":"Alexander K.","family":"Andrianov","sequence":"first","affiliation":[{"name":"Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Fuerst","sequence":"additional","affiliation":[{"name":"Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA"},{"name":"Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021, April 26). Hepatitis C. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.aad1302","article-title":"Global control of hepatitis C virus","volume":"349","author":"Cox","year":"2015","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coi.2015.06.010","article-title":"Hepatitis C virus: Why do we need a vaccine to prevent a curable persistent infection?","volume":"35","author":"Walker","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coviro.2016.09.004","article-title":"Viral evasion and challenges of hepatitis C virus vaccine development","volume":"20","author":"Pierce","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, Progress, and Challenges to Hepatitis C Vaccine Development","volume":"156","author":"Bailey","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.tim.2018.04.002","article-title":"Can broadly neutralizing monoclonal antibodies lead to a hepatitis C virus vaccine?","volume":"26","author":"Kinchen","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.chom.2018.10.012","article-title":"Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection","volume":"24","author":"Kinchen","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/infdis\/jir835","article-title":"Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion","volume":"205","author":"Raghuraman","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants","volume":"11","author":"Pashine","year":"2005","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1073\/pnas.1402981111","article-title":"Vaccines, new opportunities for a new society","volume":"111","author":"Rappuoli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nri3694","article-title":"From empiricism to rational design: A personal perspective of the evolution of vaccine development","volume":"14","author":"Rappuoli","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOP.0000000000000868","article-title":"Toward precision adjuvants: Optimizing science and safety","volume":"32","author":"Nanishi","year":"2020","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Rappuoli","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.smim.2013.05.007","article-title":"Vaccine adjuvant formulations: A pharmaceutical perspective","volume":"25","author":"Brito","year":"2013","journal-title":"Semin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sepulveda-Crespo, D., Resino, S., and Martinez, I. (2020). Innate immune response against hepatitis C virus: Targets for vaccine adjuvants. Vaccines, 8.","DOI":"10.3390\/vaccines8020313"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nri3479","article-title":"Newly described pattern recognition receptors team up against intracellular pathogens","volume":"13","author":"Broz","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Vasou, A., Sultanoglu, N., Goodbourn, S., Randall, R.E., and Kostrikis, L.G. (2017). Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: From synthetic PRR agonists to the potential of defective interfering particles of viruses. Viruses, 9.","DOI":"10.3390\/v9070186"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/erv.11.189","article-title":"Pattern recognition receptors: Sentinels in innate immunity and targets of new vaccine adjuvants","volume":"11","author":"Olive","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: You might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"npj Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/eji.200838648","article-title":"Alum adjuvanticity: Unraveling a century old mystery","volume":"38","author":"Tritto","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4049\/jimmunol.181.1.17","article-title":"Cutting Edge: Inflammasome Activation by Alum and Alum\u2019s Adjuvant Effect Are Mediated by NLRP3","volume":"181","author":"Li","year":"2008","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2009.01.004","article-title":"Mechanism of action of clinically approved adjuvants","volume":"21","author":"Lambrecht","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ilar.46.3.280","article-title":"Adjuvants and Antibody Production: Dispelling the Myths Associated with Freund\u2019s Complete and Other Adjuvants","volume":"46","author":"Stils","year":"2005","journal-title":"ILAR J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59? adjuvant: A phoenix that arose from the ashes","volume":"12","author":"Ott","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"van Diepen, M.T., Chapman, R., Moore, P.L., Margolin, E., Hermanus, T., Morris, L., Ximba, P., Rybicki, E.P., and Williamson, A.-L. (2018). The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0208310"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/21645515.2015.1071455","article-title":"Safety and tolerability evaluation of the use of Montanide ISA\u212251 as vaccine adjuvant: A systematic review","volume":"12","author":"Liu","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1586\/erv.11.126","article-title":"The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant","volume":"10","author":"Jain","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2020.12.001","article-title":"Polyphosphazene immunoadjuvants: Historical perspective and recent advances","volume":"329","author":"Andrianov","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1021\/acsabm.0c00189","article-title":"Supramolecular assembly of Toll-like receptor 7\/8 agonist into multimeric water-soluble constructs enables superior immune stimulation in vitro and in vivo","volume":"3","author":"Andrianov","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1021\/acs.biomac.6b01251","article-title":"Molecular-Level Interactions of Polyphosphazene Immunoadjuvants and Their Potential Role in Antigen Presentation and Cell Stimulation","volume":"17","author":"Andrianov","year":"2016","journal-title":"Biomacromolecules"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/jps.22367","article-title":"PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies","volume":"100","author":"Andrianov","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1016\/j.biomaterials.2014.06.043","article-title":"The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells","volume":"35","author":"Palmer","year":"2014","journal-title":"Biomaterials"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1021\/bm100603p","article-title":"Protein Stabilization in Aqueous Solutions of Polyphosphazene Polyelectrolyte and Non-Ionic Surfactants","volume":"11","author":"Marin","year":"2010","journal-title":"Biomacromolecules"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0065-2660(05)53009-8","article-title":"Pluronic Block Copolymers for Gene Delivery","volume":"53","author":"Kabanov","year":"2005","journal-title":"Adv. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.vaccine.2003.11.064","article-title":"Pluronic\u00ae F127-based systemic vaccine delivery systems","volume":"22","author":"Coeshott","year":"2004","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0264-410X(02)00540-6","article-title":"Liposomes and ISCOMs","volume":"21","author":"Kersten","year":"2003","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.addr.2004.09.006","article-title":"ISCOMATRIX\u00ae adjuvant for antigen delivery","volume":"57","author":"Pearse","year":"2005","journal-title":"Adv. Drug Delivery Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.4049\/jimmunol.166.5.3589","article-title":"Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine","volume":"166","author":"Polakos","year":"2001","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2051013614541440","article-title":"Liposomes as vaccine delivery systems: A review of the recent advances","volume":"2","author":"Schwendener","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: Helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Agger, E.M., Rosenkrands, I., Hansen, J., Brahimi, K., Vandahl, B.S., Aagaard, C., Werninghaus, K., Kirschning, C., Lang, R., and Christensen, D. (2008). Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): A versatile adjuvant for vaccines with different immunological requirements. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003116"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/CVI.00736-14","article-title":"The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice","volume":"22","author":"Wegmann","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fimmu.2016.00427","article-title":"Modulation of Primary Immune Response by Different Vaccine Adjuvants","volume":"7","author":"Ciabattini","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG Adjuvant 1018: A Case Study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lee, G.-H., and Lim, S.-G. (2021). CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B\u00ae) Update. Expert Rev. Vaccines.","DOI":"10.1080\/14760584.2021.1908133"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ni0602-499","article-title":"Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848","volume":"3","author":"Jurk","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.onc.1210913","article-title":"TLR7 and TLR8 as targets in cancer therapy","volume":"27","year":"2008","journal-title":"Oncogene"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2005.06.024","article-title":"TLR agonists as vaccine adjuvants: Comparison of CpG ODN and Resiquimod (R-848)","volume":"23","author":"Weeratna","year":"2005","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1586\/14760584.6.5.835","article-title":"Resiquimod and other immune response modifiers as vaccine adjuvants","volume":"6","author":"Tomai","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/erv.11.26","article-title":"TLR-7 and -8 agonists as vaccine adjuvants","volume":"10","author":"Tomai","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-6215(95)00278-2","article-title":"Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy","volume":"280","author":"Jacobsen","year":"1996","journal-title":"Carbohydr Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review","volume":"60","year":"2019","journal-title":"Phytomedicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","article-title":"Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants","volume":"291","author":"Vladimer","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: Interferon induction by double-stranded RNA including poly(I:C)","volume":"60","author":"Matsumoto","year":"2008","journal-title":"Adv. Drug Delivery Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1073\/pnas.0406740101","article-title":"A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses","volume":"101","author":"Jackson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.4049\/jimmunol.1100486","article-title":"Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2","volume":"187","author":"Chua","year":"2011","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"\u0160krnjug, I., Rueckert, C., Libanova, R., Lienenklaus, S., Weiss, S., and Guzm\u00e1n, C.A. (2014). The Mucosal Adjuvant Cyclic di-AMP Exerts Immune Stimulatory Effects on Dendritic Cells and Macrophages. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095728"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.vaccine.2019.07.019","article-title":"The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)\/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells","volume":"37","author":"Volckmar","year":"2019","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1021\/acs.nanolett.8b03601","article-title":"Interrogation of Antigen Display on Individual Vaccine Nanoparticles for Achieving Neutralizing Antibody Responses against Hepatitis C Virus","volume":"18","author":"Bazzill","year":"2018","journal-title":"Nano Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/acs.molpharmaceut.0c00487","article-title":"In Vivo and In Vitro Potency of Polyphosphazene Immunoadjuvants with Hepatitis C Virus Antigen and the Role of Their Supramolecular Assembly","volume":"18","author":"Andrianov","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e00704-20","DOI":"10.1128\/JVI.00704-20","article-title":"Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization","volume":"94","author":"Pierce","year":"2020","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1074\/jbc.RA120.013015","article-title":"Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine","volume":"295","author":"Center","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.msec.2018.12.088","article-title":"The adjuvant effect of C60(OH)22 nanoparticles promoting both humoral and cellular immune responses to HCV recombinant proteins","volume":"97","author":"Liu","year":"2019","journal-title":"Mater. Sci. Eng."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","author":"Choo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.vaccine.2004.06.037","article-title":"Cationic microparticles are a potent delivery system for a HCV DNA vaccine","volume":"23","author":"Singh","year":"2004","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1053\/j.gastro.2019.11.282","article-title":"Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development","volume":"158","author":"Chen","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1016\/j.vaccine.2017.10.072","article-title":"Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes","volume":"35","author":"Landi","year":"2017","journal-title":"Vaccine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e2015149118","DOI":"10.1073\/pnas.2015149118","article-title":"Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer","volume":"118","author":"Guest","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbrc.2006.12.232","article-title":"HCV core protein immunization with Montanide\/CpG elicits strong Th1\/Th2 and long-lived CTL responses","volume":"354","author":"Roohvand","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1128\/AEM.06420-11","article-title":"Production of a Particulate Hepatitis C Vaccine Candidate by an Engineered Lactococcus lactis Strain","volume":"77","author":"Parlane","year":"2011","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/BA20090216","article-title":"Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction","volume":"56","author":"Musacchio","year":"2010","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1128\/JVI.02743-07","article-title":"Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1099\/vir.0.81849-0","article-title":"Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses","volume":"87","author":"Vajdy","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e00130-17","DOI":"10.1128\/JVI.00130-17","article-title":"Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes","volume":"91","author":"Filskov","year":"2017","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.08.046","article-title":"Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses","volume":"108","author":"Fichter","year":"2016","journal-title":"Biomaterials"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1134\/S1607672918050083","article-title":"Polyprenyl Phosphates Induce a High Humoral and Cellular Response to Immunization with Recombinant Proteins of the Replicative Complex of the Hepatitis C Virus","volume":"482","author":"Masalova","year":"2018","journal-title":"Dokl. Biochem. Biophys."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/jhep.2003.50000","article-title":"Hepatitis C virus\u2013like particles combined with novel adjuvant systems enhance virus-specific immune responses","volume":"37","author":"Qiao","year":"2003","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1128\/JVI.78.13.6995-7003.2004","article-title":"Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates","volume":"78","author":"Jeong","year":"2004","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Chua, B.Y., Johnson, D., Tan, A., Earnest-Silveira, L., Sekiya, T., Chin, R., Torresi, J., and Jackson, D.C. (2012). Hepatitis C VLPs Delivered to Dendritic Cells by a TLR2 Targeting Lipopeptide Results in Enhanced Antibody and Cell-Mediated Responses. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047492"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1099\/jgv.0.000493","article-title":"Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line","volume":"97","author":"Chua","year":"2016","journal-title":"J. Gen. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1038\/s41598-018-24762-9","article-title":"Immunological responses following administration of a genotype 1a\/1b\/2\/3a quadrivalent HCV VLP vaccine","volume":"8","author":"Christiansen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_88","first-page":"41","article-title":"Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant","volume":"42","author":"Poutou","year":"2009","journal-title":"Biol. Res."},{"key":"ref_89","first-page":"1304","article-title":"A Nanoparticle-Based Hepatitis C Virus Vaccine With Enhanced Potency","volume":"221","author":"Yan","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"197984","DOI":"10.1016\/j.virusres.2020.197984","article-title":"Combination of three adjuvants enhances the immunogenicity of a recombinant protein containing the CTL epitopes of non-structural proteins of hepatitis C virus","volume":"284","author":"Kuprianov","year":"2020","journal-title":"Virus Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2013.05.007","article-title":"Neutralizing Antibodies Induced by Cell Culture\u2013Derived Hepatitis C Virus Protect Against Infection in Mice","volume":"145","author":"Akazawa","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2016-312208","article-title":"Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model","volume":"67","author":"Yokokawa","year":"2018","journal-title":"Gut"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"eaaz6225","DOI":"10.1126\/sciadv.aaz6225","article-title":"Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines","volume":"6","author":"He","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1\u2013E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J. Ex. Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Hobernik, D., and Bros, M. (2018). DNA vaccines\u2014how far from clinical use?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113605"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11598","DOI":"10.1128\/JVI.74.24.11598-11607.2000","article-title":"Enhancing B- and T-Cell Immune Response to a Hepatitis C Virus E2 DNA Vaccine by Intramuscular Electrical Gene Transfer","volume":"74","author":"Zucchelli","year":"2000","journal-title":"J. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/jgm.1217","article-title":"Synergistic effect of gene-electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination","volume":"10","author":"Arcuri","year":"2008","journal-title":"J. Gene Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1604139","DOI":"10.1002\/adfm.201604139","article-title":"Electrically Oscillating Plasmonic Nanoparticles for Enhanced DNA Vaccination against Hepatitis C Virus","volume":"27","author":"Draz","year":"2017","journal-title":"Adv. Funct. Mater."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cyto.2008.12.007","article-title":"Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine","volume":"46","author":"Hartoonian","year":"2009","journal-title":"Cytokine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"43531","DOI":"10.1038\/srep43531","article-title":"Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/iub.2109","article-title":"Listeriolysin O immunogenetic adjuvant enhanced potency of hepatitis C virus NS3 DNA vaccine","volume":"71","author":"Pouriayevali","year":"2019","journal-title":"IUBMB Life"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.4049\/jimmunol.179.7.4741","article-title":"In Vivo Electroporation Enhances the Immunogenicity of Hepatitis C Virus Nonstructural 3\/4A DNA by Increased Local DNA Uptake, Protein Expression, Inflammation, and Infiltration of CD3+ T Cells","volume":"179","author":"Tjelle","year":"2007","journal-title":"J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1016\/j.vaccine.2016.04.030","article-title":"A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines","volume":"34","author":"Levander","year":"2016","journal-title":"Vaccine"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12250-013-3291-z","article-title":"Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity","volume":"28","author":"Naderi","year":"2013","journal-title":"Virol. Sin."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/655902","article-title":"Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins","volume":"202","author":"Ray","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jir399","article-title":"Immunization of Human Volunteers With Hepatitis C Virus Envelope Glycoproteins Elicits Antibodies That Cross-Neutralize Heterologous Virus Strains","volume":"204","author":"Stamataki","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/jvh.12163","article-title":"HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN\u03b12a and Ribavirin: A randomized controlled trial","volume":"21","author":"Colombatto","year":"2014","journal-title":"J. Viral Hepatitis"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Law, J.L.M., Chen, C., Wong, J., Hockman, D., Santer, D.M., Frey, S.E., Belshe, R.B., Wakita, T., Bukh, J., and Jones, C.T. (2013). A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1\/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059776"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2004.02.002","article-title":"A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers","volume":"22","author":"Depla","year":"2004","journal-title":"Vaccine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4161\/hv.1.2.1554","article-title":"Immunogenicity and Tolerability of Intradermal Administration of an HCV E1-Based Vaccine Candidate in Healthy Volunteers and Patients with Resolved or Ongoing Chronic HCV Infection","volume":"1","author":"Batens","year":"2005","journal-title":"Hum. Vaccines"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4161\/hv.5.3.6614","article-title":"Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX\u2122 vaccine: A phase I study in healthy volunteers","volume":"5","author":"Drane","year":"2009","journal-title":"Hum. Vaccines"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.vaccine.2006.03.009","article-title":"Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects","volume":"24","author":"Firbas","year":"2006","journal-title":"Vaccine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1053\/j.gastro.2008.02.058","article-title":"Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41","volume":"134","author":"Klade","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.vaccine.2009.12.072","article-title":"Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine","volume":"28","author":"Firbas","year":"2010","journal-title":"Vaccine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2020.02.009","article-title":"IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses","volume":"73","author":"Han","year":"2020","journal-title":"J. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/6\/981\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:07:38Z","timestamp":1760162858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/6\/981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":117,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["v13060981"],"URL":"https:\/\/doi.org\/10.3390\/v13060981","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}